Xconomy Health Tech
A growing population of people with software experience plus an interest in life sciences is boosting drug development in the San Francisco Bay Area, according to panelists at an Xcelerating event.
Innovation in the San Francisco Bay Area may first bring to mind tech behemoths like Facebook and Google. But some drug development companies in the region say its openness to new ideas and the combination of software experience and life sciences expertise are boosting their prospects.
“For us inside the company, having that kind of ‘wet’ and ‘dry’—what Daphne Koller, our founder and CEO, calls that ‘bilingual’—perspective is critically important,”... Read more »
Johnson & Johnson’s global head of external innovation says there needs to be a shift in how healthcare research is funded to focus on early detection and curing rather than managing diseases.
“When you look at the investment in research in the pharma industry, it’s all designed to treat established diseases,” William Hait, global head of Johnson & Johnson (NYSE: JNJ) External Innovation, told delegates at the BIO-Europe Spring event, held digitally last week due to the coronavirus crisis.
While there have been notable exceptions—particularly in the cardiovascular diseases where Hait said it was realized early on that decreasing... Read more »